Revolution Medicines (RVMD) is trading lower as the market prices in a proposed capital raise: a public offering of $750 million of common stock and a separate public offering of $250 million of convertible senior notes due 2033. Offerings of this type often pressure shares in the near term because equity issuance is dilutive and convertible deals can create a technical “overhang” as investors hedge exposure.

The financing comes just days after RVMD’s surge tied to upbeat Phase 3 data, setting up a classic post-pop dynamic where a company raises cash into strength and traders lock in gains. With the stock up sharply into mid-April, the announcement shifted the narrative from clinical momentum to deal mechanics—pricing terms, discount, total share count, and the eventual conversion features of the notes.

Key near-term catalysts are the pricing of the common stock offering and the final terms of the convertible notes (interest rate, conversion premium, and any overallotment options). Investors will also focus on how much net cash the company adds versus the implied dilution, and whether management signals a faster commercial buildout or expanded trial plans that justify the larger balance-sheet raise.